Physician profile
Michael J Turner
NPI 1700856770
$10,732.61
in general payments reported to CMS, 2019-2025
43 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $1,686 · 2021: $1,738 · 2022: $1,562 · 2023: $1,580 · 2024: $1,576 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,315.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,210.06 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,126.56 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Janssen Pharmaceuticals, INC | $989.12 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $810.39 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $785.04 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $729.90 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $726.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $532.79 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $503.91 | 2021-2025 | |
| Abbott Laboratories | $398.22 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $341.69 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $286.78 | 2019-2023 | |
| Allergan, INC. | $273.30 | 2019-2020 | |
| Amgen INC. | $199.38 | 2019-2024 | Repatha, Otezla |
| Dexcom, INC. | $198.81 | 2021-2025 | Dexcom G6 Transmitter |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.